Murciano-Goroff, Yonina R.
Lito, Piro
Article History
First Online: 23 August 2022
Competing interests
: Y.R.M-G. has received support for travel, accommodation and expenses from AstraZeneca, honoraria from Virology Education and Projects in Knowledge (for a program funded by an educational grant from Amgen) and acknowledges associated institutional research support funded by Elucida Oncology, Endeavor Biomedicines, Hengrui USA/Jiangsu Hengrui Pharmaceuticals, Loxo Oncology at Eli Lilly, Luzsana Biotechnology and Taiho Oncology and royalties from Rutgers University Press and Wolters Kluwer. P.L. is listed as an inventor on patents filed by MSKCC on the treatment of cancers with <i>BRAF</i> or <i>KRAS</i> mutations. P.L. receives institutional research support funded by Amgen, Boehringer Ingelheim, Mirati, Revolution Medicines and Virtec Pharmaceuticals, consulting fees or honoraria from AmMax Bio, Black Diamond Therapeutics, Boehringer Ingelheim, Repare Therapeutics and Revolution Medicines and is a member of the scientific advisory board for Frontier Medicines.